EPIX - ESSA Pharma Inc.

0.2012
-0.004   -1.889%

Share volume: 5,945,141
Last Updated: 10-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 3.27%

PREVIOUS CLOSE
CHG
CHG%
$0.20
0.00
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
23%
Profitability 27%
Dept financing 13%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
-15.07%
1 Year
-87.88%
2 Year
-97.69%
Key data
Stock price
$0.20
P/E Ratio 
0.00
DAY RANGE
$0.19 - $0.21
EPS 
-$0.56
52 WEEK RANGE
$0.18 - $1.94
52 WEEK CHANGE
-$87.73
MARKET CAP 
75.461 M
YIELD 
N/A
SHARES OUTSTANDING 
47.308 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
3.54
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: David R. Parkinson
Region: US
Website: essapharma.com
Employees: 0
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

ESSA Pharma Inc. focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study. The company has collaboration agreements with Caris Life Sciences, Inc. and Bayer Consumer Care AG.

Recent news